References
- Bolon M. (2011). The newer fluoroquinolones. In: Kaye K, Kaye D, eds. Antibacterial therapy and newer agents. USA: Elsevier Inc.
- Böttcher S, Baum Hv, Hoppe-Tichy T, et al. (2001). An HPLC assay and a microbiological assay to determine levofloxacin in soft tissue, bone, bile and serum. J Pharm Biomed Anal 25:197–203.
- Casas L, Vaz S, Landoni M. (2019). Eficacia clínica de levofloxacina en el tratamiento de caninos con procesos infecciosos cutáneos y urinarios. Rev Vet UNNE 30:17–22.
- Chien SC, Wong FA, Fowler CL, et al. (1998). Double-blind evaluation of the safety and pharmacokinetics of multiple oral once daily 750-milligram and 1-gram doses of levofloxacin in healthy volunteers. Antimicrob Agents Chemother 42:885–8.
- CLSI. (2019). CLSI rationale document MR02. Fluoroquinolone breakpoints for Enterobacteriaceae and Pseudomonas aeruginosa. Wayne (PA).
- Croom K, Goa K. (2003). Levofloxacin. A review of its use in the treatment of bacterial infections in the United States. Drugs 63:2769–802.
- Farrier D. (1999). PK solutions 2.0, noncompartmental pharmacokinetics. Data analysis. USA: Ashland.
- Fish D, Chow A. (1997). The clinical pharmacokinetics of levofloxacin. Clin Pharmacokinet 32:101–19.
- Gao C-H, Yu L-S, Zeng S, et al. (2014). Personalized therapeutics for levofloxacin: a focus on pharmacokinetic concerns. Ther Clin Risk Manag 10:217–27.
- Guay RP. (2018). Chapter: quinolones. In: St. Georgie V, ed. Drug interactions in infectious diseases: antimicrobial drug interactions. Switzerland: Humana Press Springer.
- KuKanich K, KuKanich B, Guess S, et al. (2016). Effect of sucralfate on the relative bioavailability of enrofloxacin and ciprofloxacin in healthy fed dogs. J Vet Intern Med 30:108–15.
- Landoni MF, Albarellos G. (2019). Pharmacokinetics of levofloxacin after single intravenous, oral and subcutaneous administration to dogs. J Vet Pharmacol Ther 42:171–8.
- Madsen M, Messenger K, Papich M. (2019). Pharmacokinetics of levofloxacin following oral administration of a generic levofloxacin tablet and intravenous administration to dogs. Am J Vet Res 80:957–62.
- Messina MJ, Caverzán M, Prieto G, et al. (2019). Nuevo tratamiento de muestra (clean-up) para levofloxacina en plasma de caninos. Revista Científica Ab Intus, edición especial: 225.
- Papich MG. (2015). Saunders handbook of veterinary drugs-e-book: small and large animal. USA: Elsevier Health Sciences.
- Pitman S, Hoang U, Wi C, et al. (2019). Revisiting oral fluoroquinolone and multivalent cation drug–drug interactions: are they still relevant? Antibióticos 8:108.
- Rebuck J, Fish D, Abraham E. (2002). Pharmacokinetics of intravenous and oral levofloxacin in critically III adults in a medical intensive care unit. Pharmacotherapy 22: 1216–25.
- Sulochana S, Syed M, Chandrasekar D, et al. (2016). Clinical drug–drug pharmacokinetic interaction potential of sucralfate with other drugs: review and perspectives. Eur J Drug Metab Pharmacokinet 41:469–503.
- Zhang C, Liu F, Song H. (2014). Effect of lipide diet on the pharmacokinetics of levofloxacin in Beagle dogs. Chongqing Med 3184–6.